LAB vs TROW · rev $174.4M vs P/E 12, rev $7.09B
Standard Biotools Inc (LAB) versus T. Rowe Price Group Inc (TROW) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
T. Rowe Price Group Inc (TROW) is a asset management company listed on NASDAQ.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported TROW revenue for 2024-12-31 was $7.09B. Net income was $2.14B. Revenue was up 9.8% from 2023-12-31 to 2024-12-31. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
LAB currently screens at market cap $317.1M. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
Not investment advice. Open the LAB and TROW stock pages for the full models.
Not investment advice.